{
    "id": 493,
    "fullName": "GNA11 Q209L",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "GNA11 Q209L is a hotspot mutation that lies within a GTP binding region of the Gna11 protein (UniProt.org). Q209L results in a loss of Gna11 protein function as indicated by activation of downstream signaling in culture (PMID: 26778290) and increased tumor growth in mouse models (PMID: 21083380, PMID: 24141786, PMID: 23640210).",
            "references": [
                {
                    "id": 772,
                    "pubMedId": 24141786,
                    "title": "Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24141786"
                },
                {
                    "id": 8769,
                    "pubMedId": 26778290,
                    "title": "Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26778290"
                },
                {
                    "id": 8762,
                    "pubMedId": 21083380,
                    "title": "Mutations in GNA11 in uveal melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21083380"
                },
                {
                    "id": 253,
                    "pubMedId": 23640210,
                    "title": "The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23640210"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2767,
        "geneSymbol": "GNA11",
        "terms": [
            "GNA11",
            "FBH",
            "FBH2",
            "FHH2",
            "GNA-11",
            "HHC2",
            "HYPOC2"
        ]
    },
    "variant": "Q209L",
    "createDate": "05/12/2014",
    "updateDate": "07/29/2019",
    "referenceTranscriptCoordinates": {
        "id": 145027,
        "transcript": "NM_002067",
        "gDna": "chr19:g.3118944A>T",
        "cDna": "c.626A>T",
        "protein": "p.Q209L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16752,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Selumetinib (AZD6244) treatment resulted in partial response in a patient with uveal melanoma harboring GNA11 Q209L (PMID: 24938562; NCT01143402).",
            "molecularProfile": {
                "id": 550,
                "profileName": "GNA11 Q209L"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8678,
                    "pubMedId": 24938562,
                    "title": "Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24938562"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1045,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) synergized to inhibit growth in a human uveal melanoma cancer cell line harboring a GNA11 Q209L mutation in culture and in xenograft models, and demonstrated improved efficacy over either agent alone (PMID: 24141786).",
            "molecularProfile": {
                "id": 550,
                "profileName": "GNA11 Q209L"
            },
            "therapy": {
                "id": 1114,
                "therapyName": "AEB071 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 772,
                    "pubMedId": 24141786,
                    "title": "Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24141786"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10641,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, uveal melanoma cell lines harboring GNA11 Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNA11 (PMID: 22733540).",
            "molecularProfile": {
                "id": 550,
                "profileName": "GNA11 Q209L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8697,
                    "pubMedId": 22733540,
                    "title": "Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22733540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNA11 Q209L in culture (PMID: 22515704).",
            "molecularProfile": {
                "id": 550,
                "profileName": "GNA11 Q209L"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8672,
                    "pubMedId": 22515704,
                    "title": "Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22515704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16783,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FR900359 inhibited ERK activation and proliferation, and induced cell-cycle arrest and apoptosis in a uveal melanoma cell line harboring GNA11 Q209L in culture (PMID: 30567972).",
            "molecularProfile": {
                "id": 550,
                "profileName": "GNA11 Q209L"
            },
            "therapy": {
                "id": 8196,
                "therapyName": "FR900359",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14908,
                    "pubMedId": 30567972,
                    "title": "Effects of Oncogenic G\u03b1q and G\u03b111 Inhibition by FR900359 in Uveal Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30567972"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 550,
            "profileName": "GNA11 Q209L",
            "profileTreatmentApproaches": [
                {
                    "id": 11269,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "GNA11 Q209L"
                },
                {
                    "id": 11271,
                    "name": "Verteporfin",
                    "profileName": "GNA11 Q209L"
                },
                {
                    "id": 11270,
                    "name": "PKC Inhibitor (Pan)",
                    "profileName": "GNA11 Q209L"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145027,
            "transcript": "NM_002067",
            "gDna": "chr19:g.3118944A>T",
            "cDna": "c.626A>T",
            "protein": "p.Q209L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}